Epigenetic therapy can inhibit growth of ovarian cancer cells and reverse chemoresistant properties acquired from metastatic omentum.
Antineoplastic Agents
/ therapeutic use
Cell Line, Tumor
/ drug effects
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Cisplatin
/ pharmacology
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
Enzyme-Linked Immunosorbent Assay
Female
Humans
Omentum
Ovarian Neoplasms
/ drug therapy
Paclitaxel
/ pharmacology
Pilot Projects
Uterine Neoplasms
/ drug therapy
Adipose-derived stem cells
Chemoresistance
Chemotherapy
Conditioned medium
Epigenetic drugs
Omental microenvironment
Omentum
Ovarian cancer
Secretome
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
09
04
2018
revised:
21
08
2018
accepted:
01
03
2019
pubmed:
5
3
2019
medline:
14
5
2019
entrez:
5
3
2019
Statut:
ppublish
Résumé
To examine the cytotoxicity of epigenetic drugs independently and in combination with chemotherapy on ovarian cancer cells Caov-3, and to investigate their ability to acquire chemoresistance in omental microenvironments and whether epigenetic drugs can counteract this chemoresistance. A pilot study was conducted in Cooper University Hospital, NJ, USA from August 1 to October 31, 2017, among women undergoing surgeries for uterine and ovarian cancer. Cytotoxicity assays using IC Three women met the eligibility criteria and were included in the study. Epigenetic drugs alone or in combination with chemotherapy showed 85%-94% increased cytotoxicity against Caov-3 (P≤0.005). Metastatic OASCs conditioned medium showed up to 27-fold increase in tumorigenic factors and promoted chemoresistance (28%-35%; P < 0.050) against chemotherapy. Epigenetic therapy resulted in up to a 40-fold reversal in this chemoresistance. Epigenetic therapies could have an important role in treating a subgroup of ovarian cancer patients that demonstrate resistance to first-line chemotherapy.
Substances chimiques
Antineoplastic Agents
0
Paclitaxel
P88XT4IS4D
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
225-232Subventions
Organisme : Cooper Foundation
Organisme : Department of Surgery
Informations de copyright
© 2019 International Federation of Gynecology and Obstetrics.